Search

Search Constraints

You searched for: Author/Creator Sehgal, Alison

Search Results

1. 1105. The Burden of Infections Prior to Chimeric Antigen Receptor (CAR) Modified T-cell Therapy Predicts Post-CAR T-cell Infectious Complications. (31st December 2020)

2. A nomogram using cytogenetics, TP53, and NPM1 mutational status can predict responses to induction chemotherapy in AML. Issue 13 (10th November 2022)

3. A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia. Issue 11 (2nd November 2018)

4. ICU intervention during induction chemotherapy for adult patients with newly diagnosed acute myeloid leukemia. (September 2016)

5. ICU intervention during induction chemotherapy for adult patients with newly diagnosed acute myeloid leukemia. (September 2016)

6. Inferior outcome after allogeneic transplant in first remission in high‐risk AML patients who required more than two cycles of induction therapy. Issue 8 (August 2015)

7. Leukapheresis in patients newly diagnosed with acute myeloid leukemia. Issue 2 (October 2016)

8. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Issue 8 (August 2022)

9. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Issue 10254 (19th September 2020)

10. Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease. Issue 11 (10th April 2022)